Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 552

Results For "C"

10382 News Found

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
News | April 29, 2023

Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab

This approval reflects Biocon Biologics' compliance with the highest international regulatory standards


RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
News | April 29, 2023

RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr

Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23


Atul appoints Rangaswamy Iyer as Independent Director
People | April 29, 2023

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years


Evonik starts construction of new U.S. facility for pharmaceutical lipids
News | April 29, 2023

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness


TPAG organizes Thalassemia & SCD prevention discussion
News | April 29, 2023

TPAG organizes Thalassemia & SCD prevention discussion

The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally


Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
News | April 28, 2023

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects


Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
News | April 28, 2023

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework


Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
News | April 28, 2023

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.


Ipca Laboratories gets 3 observations for Piparia, Silvassa unit
Drug Approval | April 27, 2023

Ipca Laboratories gets 3 observations for Piparia, Silvassa unit

The company will submit its comprehensive response on these observations to the US FDA within the stipulated time